Avanir Pharmaceuticals,
Inc. AVNR today announced that the Committee for Medicinal Products
for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a
positive opinion for NUEDEXTA^® (dextromethorphan hydrobromide and quinidine
sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar
affect (PBA), irrespective of neurologic cause. In addition, the CHMP also
recommended approval of two dose strengths of NUEDEXTA; 20/10 mg and 30/10 mg
capsules.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in